Please login to the form below

Not currently logged in
Email:
Password:

Aduro

This page shows the latest Aduro news and features for those working in and with pharma, biotech and healthcare.

AbbVie cures STING fever with Mavupharma acquisition

AbbVie cures STING fever with Mavupharma acquisition

Shortly afterwards, Aduro reported data for its ADU-S100, which seemed to far a little better than MK-1454 in its phase 1 trial but was still a long way from ... Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015.

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can ... marked more by failures than successes, with a string of candidates

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

  • Pharma deals in March 2015 Pharma deals in March 2015

    One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214.

  • Pharma deals during October 2014 Pharma deals during October 2014

    on Aduro's novel LADD [live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce an innate immune response] immunotherapy platform. ... Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics